Kurs & Likviditet
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
2023-06-28 16:45:11
Reference is made to the stock exchange announcement made earlier today by
Nordic Nanovector ASA ("Nordic Nanovector" or the "Company"), where the Company
announced, among other things, that the annual general meeting had elected new
board members to the board of directors, including electing former interim CFO &
CEO Ludvik Sandnes as new chairman.
Against this background, the board of directors of Nordic Nanovector has today
appointed Mr. Alf Bjørnseth as new chief executive officer of Nordic Nanovector.
The appointment will be effective as of today. Under Mr. Bjørnseth's employment
agreement with the Company, his remuneration comprises of a cash compensation
whereby at least half of the cash compensation shall be converted into
restricted share units ("RSU's") in the Company. The number of RSUs to be
granted by the board of directors to Mr. Bjørnseth shall be determined based on
the average trading price of the Company's shares over the 10 days up to and
including 27 June 2023.
About Nordic Nanovector
Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care.
This information is subject of the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.
Ludvik Sandnes, Interim CEO & CFO
Cell: +47 907 43 017
Email: ir@nordicnanovector.com